Business Standard

Sun Pharma gains ahead of Q2 results

The company may report 29% y-o-y growth in its consolidated net profit at Rs 772 crore in Q2.

Read more on:    Cipla | Ranbaxy | Sun Pharma
Related News

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

The stock opened at Rs 700 and hit a high of Rs 714 on the NSE. A combined 684,427 shares have changed hands on the counter so far against an average 609,000 shares that were traded daily in past ten trading days.

According to an average analyst estimates, may report 29% year-on-year growth in its consolidated net profit at Rs 772 crore in the September 2012 quarter. The company had reported profit of Rs 598 crore in previous year quarter.

“Sun Pharma is likely to report strong revenue growth at 50% led by 18% growth in domestic formulations, 49% growth in Taro US revenues and niche launches in US viz. Lipodex and Stalevo. Operating margins are likely to expand by over 600 bps to 40%,” according to analyst at Emkay Global Financial Services.

Read more on:   
|
|

Read More

BSE launches carbon index

Premier bourse BSE, in collaboration with the UK government, today launched BSE Carbonex, the first-of-its-kind index in India or any emerging market ...

Quick Links

 

Market News

Plea against MF body as self-regulator admitted

The Securities Appellate Tribunal (SAT) has admitted an appeal against a decision on approval given for setting up a regulatory organisation for ...

Deepak Fertilisers: Boost in case of MCF acquisition

Deepak Fertilisers, earlier in July last year, had brought 24.45% stake in MCF

L&T Finance's asset stress rises

But improving profits of smaller subsidiaries are likely to sustain

Today's picks

Nifty, Bank Nifty, Larsen & Toubro, Cairn India & Ambuja Cement

Edelweiss announces buyback at Rs 45 a share

The total amount on the buyback will not exceed Rs 135 cr

Back to Top